KPC Pharmaceuticals Inc (600422) - Net Assets
Based on the latest financial reports, KPC Pharmaceuticals Inc (600422) has net assets worth CN¥6.44 Billion CNY (≈ $942.00 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.98 Billion ≈ $1.61 Billion USD) and total liabilities (CN¥4.54 Billion ≈ $664.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KPC Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.44 Billion |
| % of Total Assets | 58.63% |
| Annual Growth Rate | 15.2% |
| 5-Year Change | 40.51% |
| 10-Year Change | 92.18% |
| Growth Volatility | 56.44 |
KPC Pharmaceuticals Inc - Net Assets Trend (1997–2025)
This chart illustrates how KPC Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see KPC Pharmaceuticals Inc stock valuation.
Annual Net Assets for KPC Pharmaceuticals Inc (1997–2025)
The table below shows the annual net assets of KPC Pharmaceuticals Inc from 1997 to 2025. Also explore how fast is KPC Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.94 Billion ≈ $1.02 Billion |
+2.89% |
| 2024-12-31 | CN¥6.75 Billion ≈ $987.19 Million |
-15.19% |
| 2023-12-31 | CN¥7.95 Billion ≈ $1.16 Billion |
+54.68% |
| 2022-12-31 | CN¥5.14 Billion ≈ $752.51 Million |
+4.09% |
| 2021-12-31 | CN¥4.94 Billion ≈ $722.92 Million |
+7.34% |
| 2020-12-31 | CN¥4.60 Billion ≈ $673.51 Million |
+6.20% |
| 2019-12-31 | CN¥4.33 Billion ≈ $634.22 Million |
+9.77% |
| 2018-12-31 | CN¥3.95 Billion ≈ $577.79 Million |
+4.63% |
| 2017-12-31 | CN¥3.77 Billion ≈ $552.21 Million |
+4.48% |
| 2016-12-31 | CN¥3.61 Billion ≈ $528.55 Million |
+8.28% |
| 2015-12-31 | CN¥3.34 Billion ≈ $488.14 Million |
+62.75% |
| 2014-12-31 | CN¥2.05 Billion ≈ $299.93 Million |
+9.07% |
| 2013-12-31 | CN¥1.88 Billion ≈ $274.98 Million |
+77.83% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.63 Million |
+15.17% |
| 2011-12-31 | CN¥917.52 Million ≈ $134.26 Million |
+11.87% |
| 2010-12-31 | CN¥820.15 Million ≈ $120.01 Million |
+11.08% |
| 2009-12-31 | CN¥738.35 Million ≈ $108.04 Million |
+10.12% |
| 2008-12-31 | CN¥670.50 Million ≈ $98.12 Million |
+5.56% |
| 2007-12-31 | CN¥635.17 Million ≈ $92.94 Million |
+8.79% |
| 2006-12-31 | CN¥583.86 Million ≈ $85.44 Million |
-0.71% |
| 2005-12-31 | CN¥588.02 Million ≈ $86.05 Million |
-18.69% |
| 2004-12-31 | CN¥723.20 Million ≈ $105.83 Million |
+9.58% |
| 2003-12-31 | CN¥659.95 Million ≈ $96.57 Million |
+15.54% |
| 2002-12-31 | CN¥571.17 Million ≈ $83.58 Million |
+2.04% |
| 2001-12-31 | CN¥559.74 Million ≈ $81.91 Million |
+0.38% |
| 2000-12-31 | CN¥557.64 Million ≈ $81.60 Million |
+295.69% |
| 1999-12-31 | CN¥140.93 Million ≈ $20.62 Million |
+0.39% |
| 1998-12-31 | CN¥140.38 Million ≈ $20.54 Million |
+6.27% |
| 1997-12-31 | CN¥132.10 Million ≈ $19.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to KPC Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 374407474465.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.73 Billion | 69.65% |
| Common Stock | CN¥756.98 Million | 14.12% |
| Other Comprehensive Income | CN¥388.26 Million | 7.24% |
| Other Components | CN¥482.31 Million | 8.99% |
| Total Equity | CN¥5.36 Billion | 100.00% |
KPC Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of KPC Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Centuria Capital Group
AU:CNI
|
$914.03 Million |
|
Mader Group Ltd
AU:MAD
|
$914.16 Million |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
$914.16 Million |
|
Ningbo Donly Co Ltd
SHE:002164
|
$914.24 Million |
|
Rezolve AI Limited Ordinary Shares
NASDAQ:RZLV
|
$913.32 Million |
|
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
|
$912.83 Million |
|
NCC Limited
NSE:NCC
|
$912.63 Million |
|
Yubico AB
ST:YUBICO
|
$912.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KPC Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,253,648,545 to 5,362,259,636, a change of 108,611,091 (2.1%).
- Net income of 349,940,800 contributed positively to equity growth.
- Dividend payments of 227,092,727 reduced retained earnings.
- Other comprehensive income decreased equity by 23,376,545.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥349.94 Million | +6.53% |
| Dividends Paid | CN¥227.09 Million | -4.24% |
| Other Comprehensive Income | CN¥-23.38 Million | -0.44% |
| Other Changes | CN¥9.14 Million | +0.17% |
| Total Change | CN¥- | 2.07% |
Book Value vs Market Value Analysis
This analysis compares KPC Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 59.86x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.14 | CN¥8.25 | x |
| 1998-12-31 | CN¥0.14 | CN¥8.25 | x |
| 1999-12-31 | CN¥0.16 | CN¥8.25 | x |
| 2000-12-31 | CN¥0.81 | CN¥8.25 | x |
| 2001-12-31 | CN¥0.83 | CN¥8.25 | x |
| 2002-12-31 | CN¥0.60 | CN¥8.25 | x |
| 2003-12-31 | CN¥0.68 | CN¥8.25 | x |
| 2004-12-31 | CN¥0.75 | CN¥8.25 | x |
| 2005-12-31 | CN¥0.82 | CN¥8.25 | x |
| 2006-12-31 | CN¥0.83 | CN¥8.25 | x |
| 2007-12-31 | CN¥0.91 | CN¥8.25 | x |
| 2008-12-31 | CN¥0.97 | CN¥8.25 | x |
| 2009-12-31 | CN¥1.06 | CN¥8.25 | x |
| 2010-12-31 | CN¥1.17 | CN¥8.25 | x |
| 2011-12-31 | CN¥1.30 | CN¥8.25 | x |
| 2012-12-31 | CN¥1.49 | CN¥8.25 | x |
| 2013-12-31 | CN¥2.70 | CN¥8.25 | x |
| 2014-12-31 | CN¥2.44 | CN¥8.25 | x |
| 2015-12-31 | CN¥4.20 | CN¥8.25 | x |
| 2016-12-31 | CN¥4.51 | CN¥8.25 | x |
| 2017-12-31 | CN¥4.67 | CN¥8.25 | x |
| 2018-12-31 | CN¥4.97 | CN¥8.25 | x |
| 2019-12-31 | CN¥5.51 | CN¥8.25 | x |
| 2020-12-31 | CN¥5.86 | CN¥8.25 | x |
| 2021-12-31 | CN¥6.31 | CN¥8.25 | x |
| 2022-12-31 | CN¥6.63 | CN¥8.25 | x |
| 2023-12-31 | CN¥8.62 | CN¥8.25 | x |
| 2024-12-31 | CN¥6.97 | CN¥8.25 | x |
| 2025-12-31 | CN¥7.05 | CN¥8.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KPC Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.53%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.32%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.20x
- Recent ROE (6.53%) is below the historical average (10.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 12.72% | 4.05% | 0.89x | 3.51x | CN¥2.36 Million |
| 1998 | 27.01% | 6.09% | 0.97x | 4.55x | CN¥15.17 Million |
| 1999 | 24.26% | 5.26% | 1.04x | 4.42x | CN¥14.05 Million |
| 2000 | 7.60% | 7.60% | 0.64x | 1.56x | CN¥-12.31 Million |
| 2001 | 7.39% | 7.85% | 0.64x | 1.47x | CN¥-13.56 Million |
| 2002 | 8.40% | 8.83% | 0.66x | 1.44x | CN¥-8.50 Million |
| 2003 | 11.73% | 10.58% | 0.70x | 1.58x | CN¥10.38 Million |
| 2004 | 9.54% | 9.97% | 0.55x | 1.75x | CN¥-3.06 Million |
| 2005 | -8.60% | -3.69% | 0.98x | 2.39x | CN¥-96.38 Million |
| 2006 | 0.51% | 0.23% | 1.02x | 2.15x | CN¥-49.78 Million |
| 2007 | 5.06% | 2.25% | 1.08x | 2.07x | CN¥-28.38 Million |
| 2008 | 5.30% | 2.45% | 1.13x | 1.91x | CN¥-28.54 Million |
| 2009 | 8.76% | 4.06% | 1.15x | 1.87x | CN¥-8.26 Million |
| 2010 | 11.64% | 4.71% | 1.28x | 1.93x | CN¥12.05 Million |
| 2011 | 15.90% | 5.38% | 1.48x | 1.99x | CN¥48.31 Million |
| 2012 | 19.36% | 6.03% | 1.40x | 2.29x | CN¥87.88 Million |
| 2013 | 13.18% | 6.46% | 1.24x | 1.64x | CN¥55.82 Million |
| 2014 | 15.01% | 6.69% | 1.43x | 1.57x | CN¥96.41 Million |
| 2015 | 12.71% | 8.56% | 0.99x | 1.49x | CN¥89.67 Million |
| 2016 | 11.45% | 7.98% | 0.94x | 1.52x | CN¥51.50 Million |
| 2017 | 9.00% | 5.64% | 0.92x | 1.73x | CN¥-36.49 Million |
| 2018 | 8.78% | 4.72% | 1.03x | 1.80x | CN¥-46.52 Million |
| 2019 | 10.83% | 5.59% | 1.09x | 1.77x | CN¥34.69 Million |
| 2020 | 10.26% | 5.92% | 0.95x | 1.82x | CN¥11.79 Million |
| 2021 | 10.61% | 6.15% | 0.93x | 1.86x | CN¥29.33 Million |
| 2022 | 7.69% | 4.63% | 0.88x | 1.89x | CN¥-115.12 Million |
| 2023 | 8.24% | 6.41% | 0.69x | 1.87x | CN¥-115.54 Million |
| 2024 | 12.34% | 7.71% | 0.67x | 2.40x | CN¥122.72 Million |
| 2025 | 6.53% | 5.32% | 0.56x | 2.20x | CN¥-186.29 Million |
Industry Comparison
This section compares KPC Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,877,324,223
- Average return on equity (ROE) among peers: 8.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KPC Pharmaceuticals Inc (600422) | CN¥6.44 Billion | 12.72% | 0.71x | $913.85 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $589.07 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $422.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $2.46 Billion | 15.95% | 0.27x | $4.31 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.17 Billion | 10.59% | 0.88x | $2.30 Billion |
| Wedge Industrial Co Ltd (000534) | $1.41 Billion | 5.42% | 0.68x | $1.73 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $32.60 Million | 12.25% | 0.82x | $13.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.54 Billion | 7.70% | 0.92x | $945.43 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $380.02 Million | 7.98% | 0.67x | $320.64 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $1.01 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.11 Billion |
About KPC Pharmaceuticals Inc
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, ant… Read more